News
Researchers at ICO and IDIBELL participate in an international study that measures the impact of cervical cancer elimination goals
By 2030, 90% of girls should be vaccinated, 70% of women screened, and 90% of women with precancerous lesions treated
State of ‘hibernation’ keeps haematopoietic stem cells young
All tissues age. The blood-forming system is especially affected by ageing processes. Haematopoietic stem cells, the precursors to blood and immune cells, age exceptionally fast, losing the ability to divide and regenerate. This weakens the immune system and increases the risk of blood cancer. An international team led by researchers from Ulm and Barcelona has […]
An IDIBELL and UB research team demonstrates the involvement of glucose in the growth of tumor cells
Tumors take a great energy expenditure to grow and proliferate. Cancer cells are, in fact, addicted to the main fuel of cellular metabolism, glucose. The molecular machinery that degrades this sugar for energy (the so-called glycolytic enzymes) is overexpressed in tumor cells. But this is not the only characteristic that differentiates the metabolism of tumor […]
IDIBELL and Alba Pérez Foundation take a new step forward to develop a treatment for Ewing’s sarcoma
The Alba Pérez Foundation has signed a framework collaboration agreement with the Bellvitge Biomedical Research Institute that aims to support research projects related to Ewing’s sarcoma, an investigation led by Dr. Òscar Martínez-Tirado, head of IDIBELL’s Sarcomas group. Along the same lines, and making a new step forward, both entities have also signed a specific […]
The researcher Purificación Muñoz receives the V Martí Via prize
Dr. Purificación Muñoz, a researcher at the IDIBELL (Oncobell Program), has been awarded with the V Martí Vía Prize for cancer research, an award given annually by the Vallformosa Foundation and GESCO Family. The grant is endowed with 30,000 euros. This amount is assigned, year after year, to professionals and researchers from areas related to pediatric […]
ICO and IDIBELL researchers study the risk of false positives in colon screening during the period 2000-2017
Screening programs allow to detect the disease when it is in its initial stages to treat it in time and increase the chances of cure. Despite its benefits, there may be a small group of patients who may suffer the consequences of a ‘false positive’, this means that the blood found in the stool may be due to benign pathologies and not cancer.
Resolution of the Call for Expression of Interest (EoI) for Collaborative Projects on Regenerative Medicine 2019
Once the period for applications submission is finished, all the documentation provided has been reviewed and the list for funded EoI is approved. The Assessment Committee, met on October 8th, in accordance with the criteria described in the call, has evaluated the Collaborative Projects and has raised a list of proposals selected to be funded. […]
Dr. Silvia de Sanjosé recognized as one of the most influential researchers of the decade
Dr. Silvia de Sanjosé (IDIBELL-ICO) has been recently recognized as a Highly Cited Researcher. She leads the Infections and Cancer group, whose research focuses on the fight between viruses and hosts from an evolutionary perspective: the antiviral mechanisms which animals have developed and the antiviral strategies which have contributed to virus selection. They explore the […]
IDIBELL and Pharmacelera sign a research agreement to find new drugs with anticancer applications
Researchers at Bellvitge Biomedical Research Institute will develop a research project with the company Pharmacelera to look for new molecules that block the cohesin complex, with applications in several difficult-to-treat cancers, such as myeloid leukemia, glioblastomas, Ewing sarcomas, colon cancer and bladder cancer